Seeking Alpha

Ambit will not seek accelerated approval for quizartinib based on Phase 2 data

  • Ambit Biosciences (AMBI) will not submit an NDA for accelerated approval of
    quizartinib based on Phase 2 and Phase 2b data as the FDA does not agree that CR with incomplete hematologic recovery "represents a surrogate endpoint reasonably likely to predict clinical benefit."
  • After getting feedback from the regulator, the company still plans to "conduct a randomized, controlled Phase 3 clinical trial in relapsed/refractory FLT3-ITD positive AML patients."
  • OS will be the endpoint.
  • The company says it "remains committed to moving quizartinib through its late stage development as expeditiously as possible." (PR)
  • Shares are halted.
From other sites
Comments (1)
  • toosmarttofail
    , contributor
    Comments (610) | Send Message
    The FDA sure doesn't like new drugs these days, just as Big Pharma stocks are at all-time highs.
    5 Dec 2013, 12:22 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs